secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0000950130-25-000140
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma appoints Usman Azam as CEO, succeeding Daniel Passeri who transitions to advisor
--------------------------------------------------------------------------------

- Usman Azam appointed President and CEO effective Sept 29, 2025; succeeds Daniel Passeri who retires and becomes strategic advisor.
- Azam receives base salary $620,000, bonus target 50% of base, stock options for 2.25M shares (1.875M time-based + 375K performance-based).
- Passeri receives lump sum severance of $838,750, 12-month equity vesting acceleration, and COBRA for 18 months.
- Passeri advisor agreement: stock option for 375K shares tied to financing milestone, term through March 30, 2026, with continued equity vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000095013025000140/0000950130-25-000140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000095013025000140/cue-20250926.htm
  HTML page:      https://secwatch.observer/filing/0000950130-25-000140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer